Literature DB >> 13190428

Refractory heart failure.

W A SODEMAN.   

Abstract

Any patient with so-called "refractory" heart failure should be looked upon as suboptimally handled. The patient should be studied for possible development of new disturbances, either inside or outside the vascular system, which, at the same time, have a bearing upon the heart failure.The entire therapeutic program should be reviewed to be sure that all aspects of therapy have been evaluated satisfactorily and established optimally. If diuretics, especially mercurial diuretics, have been given, the possible complications of such therapy, particularly in terms of electrolyte imbalance, should be considered. It is only through a general survey of the patient for an evaluation of these factors that they may be found and therapy instituted to minimize or eliminate them.

Entities:  

Keywords:  CONGESTIVE HEART FAILURE

Mesh:

Substances:

Year:  1954        PMID: 13190428      PMCID: PMC1532128     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  6 in total

1.  Electrolyte disturbances associated with mercurial diuretic therapy in congestive heart failure.

Authors:  H L HOLLEY; R S HOGAN
Journal:  Int Rec Med Gen Pract Clin       Date:  1953-10

2.  Edema and hyponatremia.

Authors:  L G WELT
Journal:  AMA Arch Intern Med       Date:  1952-06

3.  The therapeutic range of gitalin (amorphous) compared with other digitalis preparations.

Authors:  R C BATTERMAN; A C DEGRAFF; O A ROSE
Journal:  Circulation       Date:  1952-02       Impact factor: 29.690

4.  Some clinical aspects of refractory heart failure.

Authors:  L A SOLOFF
Journal:  Mod Concepts Cardiovasc Dis       Date:  1950-08

5.  Observations on electrolyte balance during mercurial diuresis in congestive heart failure.

Authors:  W B SCHWARTZ; W M WALLACE
Journal:  J Clin Invest       Date:  1950-06       Impact factor: 14.808

6.  An example of cellular hyperosmolarity.

Authors:  L G WELT; J ORLOFF; D M KYDD; J E OLTMAN
Journal:  J Clin Invest       Date:  1950-07       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.